Sign inJoin waitlistJoin the waitlist

MM

Matthew Mei

Program Director, Hematology and Medical Oncology Fellowship Program · City of Hope National Medical Center

Credentials: · · · ·

History

Hematology and Medical Oncology Fellowship · City of Hope National Medical Center
Present
City of Hope National Medical Center
Present
City of Hope National Medical Center
Present

Hematology and Medical Oncology
City of Hope National Medical Center
2011–2014
Internal Medicine
University of California-San Francisco
2007–2010
Case Western Reserve Univ Sch of Med
2003–2007
Harvard University
2003

Research

Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
Journal of Clinical Oncology · 2020 · 286 citations
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma
New England Journal of Medicine · 2024 · 205 citations
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
Clinical Cancer Research · 2021 · 181 citations

Stephen Forman
58 papers
AH
Alex Herrera
46 papers
Ryotaro Nakamura
30 papers
Elizabeth Budde
29 papers
Ibrahim Aldoss
28 papers
VP
Vinod Pullarkat
28 papers
Leslie Popplewell
27 papers
AS
Anthony Stein
25 papers
Guido Marcucci
25 papers
Haris Ali
23 papers
AS
Amandeep Salhotra
21 papers
Monzr Al Malki
20 papers

Clinical trials

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2026–2029
Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes
Principal investigator · Not yet recruiting · Early phase 1
City of Hope Medical Center
2026
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
Principal investigator · Recruiting · Phase 2
City of Hope Medical Center
2024–2028
Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study
Principal investigator · Active not recruiting · Phase 2
City of Hope Medical Center
2023–2026